CBD For Coronavirus? New Study Adds Evidence For Cannabis

New Post Public Reply Private Reply Replies (0) Message Board
Kgem
192
CBD For Coronavirus? New Study Adds Evidence For Cannabis As Covid-19 Treatment

Emily Earlenbaugh Contributor Vices (I cover cannabis’ intersection with science, culture, and wellness).

As we continue to see outbreaks of the novel coronavirus surging, many are waiting and hoping for treatments to be developed that might treat, cure or prevent the potentially deadly disease. In a surprising turn of events, cannabis is on the list of potential treatments.
 
While researchers are exploring many different possibilities in combating COVID-19, some researchers are looking into whether cannabis or cannabis derived CBD might offer benefits for those suffering from severe forms of this infection. Interestingly, there have been several different ways researchers have suggested CBD might help, including its ability to reduce ACE2 expression and pro-inflammatory cytokine production to fight lung inflammation, and it’s potential as an antiviral. But few studies have tested these theories with actual experimentation. 
 
Now new evidence is adding support to the theory that cannabis derived CBD may help those suffering from the severe lung inflammation that occurs in more serious cases of COVID-19. The study from researchers at Augusta University in Georgia suggests  that CBD may positively impact ARDS or acute respiratory distress syndrome - a dangerous symptom in COVID-19 caused by an overactive inflammatory response. This is sometimes referred to as a ‘cytokine storm’. The authors of the study explain that “currently, other than supportive measures, there is no definitive cure for ARDS, illustrating the urgent need for creative and effective therapeutic modalities to treat this complex condition.”

But CBD may be able to help treat this dangerous symptom of COVID-19. The researchers suggest CBD may be able to help by reducing pro-inflammatory cytokine production, fighting off the storm. By reducing specific cytokines such as interleukin (IL)-6, IL-1b, and IL-17, we may be able to bring down the inflammation and thus end the respiratory distress and damage. And the results of these researchers' experiments supported this theory. 

The research itself was performed on mice, who were first given a treatment called Poly(I:C) to artificially induce ARDS, with symptoms similar to what we see in severe COVID-19 patients. This created a cytokine storm, reduced the blood oxygen saturation by 10%, and even produced structural damages to the lungs in mice subjects. Then after the mice were experiencing the cytokine storm and coinciding respiratory distress, they were given CBD. And the results showed just how powerful CBD can be when treating ARDS. “These symptoms were totally or partially reversed and returned to the level and condition of the normal after treatment with CBD” the authors report. 

In particular, mice treated with CBD saw reduced expression of IL-6, an important marker for cytokine storms, and lowered the levels of other proinflammatory cytokines. While the Poly I:C) spiked inflammatory markers, “CBD treatment reversed all these inflammatory indices and partially re-established homeostasis” the authors explain. Mice treated with CBD also had increases in lymphocyte levels in their blood, which are important white blood cells for fighting off infections. 

Researchers on the study say that CBD could play an immunotherapeutic role in treating severe respiratory viral infections like COVID-19, based on the present findings.
 
“The current data support the notion that the anti-inflammatory function of CBD may reduce cytokine storm and mitigate the effects of exaggerated inflammation” they explain. They add that “considering all potential regulatory effects of CBD as well as the vast distribution of endocannabinoid system in the body, it is plausible that CBD may be used as a therapeutic candidate in the treatment of various inflammatory conditions including COVID-19 and other virus-induced ARDS.”

Of course, this is an early study, and more research needs to be done - particularly on actual human subjects with COVID-19 related ARDS.

While we may have to wait for more research before this is being used as an active treatment for COVID-19, this study gives us good reason to hope that CBD might eventually be harnessed to help fight ARDS. It also adds to the chorus of researchers and cannabis advocates suggesting we look further into cannabis and its potential to fight this deadly disease.



https://www.forbes.com/sites/emilyearlenbaugh...eafccb382d



Additional articles:

Cannabis May Reduce Deadly COVID-19 Lung Inflammation: Researchers Explain Why

Synthetic Cannabinoid Drug For Covid-19 Approved For Phase-1 Clinical Trials






Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 2

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 7

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 10

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 2

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 8

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 6

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 2

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 4

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 4

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 3

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading

Top 5 Most Recently Viewed Articles

Discovering High-Yield Dividend Opportunities Today

Updated Category News Views 46

Ares Capital got traders buzzing back when it offered a solid yield of around 9%. It stood out as the largest publicly traded business development company (BDC) globally, which made income-focused investors take notice. But here’s the kicker: BDCs like Ares can sidestep corporate taxes if they hand out most of their earnings as dividends, creating a prime hunting ground...

Continue Reading
Anthony DiSilvestro Joins Keurig Dr Pepper as CFO

Updated Category News Views 175

Keurig Dr Pepper Welcomes New Chief Financial Officer Keurig Dr Pepper (NASDAQ: KDP) recently announced an exciting leadership change with the appointment of Anthony DiSilvestro as its new Chief Financial Officer. This important transition marks a significant step as DiSilvestro steps into his role immediately, bringing over four decades of extensive experience across...

Continue Reading
Elisa's New Branding: Introducing Elisa Industriq for Growth

Updated Category News Views 237

Elisa Unveils Elisa Industriq: A New Era in Software Solutions Elisa Oyj is excited to announce a significant milestone as it consolidates its international digital services under a unified brand known as Elisa Industriq. This initiative aims to streamline its software offerings and create a robust identity within the market. Following this change, Elisa will report the...

Continue Reading
Illinois American Water Backs United Way with Grants

Updated Category News Views 15

Driving Community Support Through Strategic Grants The American Water Charitable Foundation and Illinois American Water are making waves by putting their money where their mouth is, delivering a batch of state strategic impact grants to United Way organizations that promise to spark some serious change. It’s not every day you see such a duo diving into local communities...

Continue Reading
Essity Faces Early Bond Repayment Demand Amid Dispute

Updated Category News Views 43

Essity Faces Early Bond Repayment Demand Amid Dispute Essity has found itself in a challenging situation. Recently, a handful of bondholders have made a demand for the early repayment of bonds that are set to mature in the upcoming years of 2029, 2030, and 2031. This unexpected request has prompted Essity to reaffirm its position and contest the claims of these...

Continue Reading